Dark

Check out our API

CKPT
Checkpoint Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

May 29, 2025

4.26USD+0.709%(+0.03)8,666,849

Pre-market

0.00USD-100.000%(-4.23)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

04:30PM EST Checkpoint Therapeutics to Participate in the B. Riley GlobeNewswire Inc

02:32PM EST Mid-Afternoon Market Update: Dow Turns Higher; General Electric Shares Slide Benzinga

12:14PM EST Mid-Day Market Update: Nasdaq Tumbles 300 Points; Sierra Oncology Shares Jump Benzinga

10:02AM EST HC Wainwright & Co. Maintains Buy on Checkpoint Therapeutics, Raises Price Target to $26 Benzinga

07:59AM EST Checkpoint Therapeutics Announces Positive Topline Results From The Registration-Enabling Trial Of Cosibelimab RTTNews

07:37AM EST Checkpoint Therapeutics Announces Topline Results From Registration-Enabling Trial Of Cosibelimab In Metastatic Cutaneous Squamous Cell Carcinoma; Study Met Primary Endpoint With 47.4% Objective Response Rate Benzinga

07:30AM EST -- Study met primary endpoint with 47.4% objective response rate -- Safety and tolerability profile consistent with previously reported data -- Planned BLA submission on track for later this year -- Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET GlobeNewswire Inc

Dec 8, 2021

08:33AM EST Checkpoint Therapeutics Announces Initiation Of CONTERNO Phase 3 Trial Of Cosibelimab Combined With Chemotherapy In Patients With First-Line Non-Squamous Non-Small Cell Lung Cancer Benzinga

08:30AM EST Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 GlobeNewswire Inc

Nov 5, 2021

09:33AM EDT Checkpoint Therapeutics Q3 EPS $(0.14) Down From $(0.09) YoY Benzinga

Sep 22, 2021

08:30AM EDT Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual GlobeNewswire Inc

Sep 9, 2021

08:30AM EDT Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: GlobeNewswire Inc

Aug 5, 2021

06:14PM EDT Checkpoint Therapeutics Q2 EPS $(0.12) Down From $(0.09) YoY, Sales $155.00K Up From $42.00K YoY Benzinga

Jun 9, 2021

02:50PM EDT Mid-Afternoon Market Update: Dow Drops Over 50 Points; Comtech Telecommunications Shares Plunge Benzinga

12:24PM EDT Mid-Day Market Update: United Natural Foods Falls On Sales Miss; Aethlon Medical Shares Jump Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Mixed; Campbell Soup Profit Misses Views Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2021 Benzinga

06:43AM EDT B. Riley Securities Initiates Coverage On Checkpoint Therapeutics with Buy Rating, Announces Price Target of $18 Benzinga

Jun 3, 2021

08:02AM EDT Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics Benzinga

May 12, 2021

08:02AM EDT Checkpoint Therapeutics Announces Completion Of Enrollment In Registration-Enabling Trial Of Cosibelimab In Metastatic Cutaneous Squamous Cell Carcinoma Benzinga

08:00AM EDT -- Top-line results expected in 4Q 2021 -- Targeting BLA submission in 1H 2022 -- Market-disruptive pricing planned in $25 billion and growing PD-(L)1 market GlobeNewswire Inc

May 6, 2021

05:39PM EDT Checkpoint Therapeutics Q1 EPS $(0.09) Down From $(0.06) YoY, Sales $68.00K Down From $972.00K YoY Benzinga

Mar 9, 2021

04:34PM EST Checkpoint Therapeutics Reports FY20 EPS $(0.41) Up From $(0.70) YoY, Sales $1.069M Down From $1.708M YoY Benzinga

04:30PM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights. GlobeNewswire Inc

Mar 4, 2021

08:00AM EST Checkpoint Therapeutics to Participate in H.C. Wainwright Global GlobeNewswire Inc

Mar 1, 2021

08:30AM EST Checkpoint Therapeutics Announces Formation of Scientific Advisory GlobeNewswire Inc

Jan 20, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2021 Benzinga

06:34AM EST Cantor Fitzgerald Initiates Coverage On Checkpoint Therapeutics with Overweight Rating, Announces Price Target of $16 Benzinga

Jan 6, 2021

08:30AM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. GlobeNewswire Inc

Dec 17, 2020

05:24PM EST Checkpoint Therapeutics Reports Offering Of $100M In Shares Benzinga

Nov 9, 2020

08:29AM EST Checkpoint Therapeutics Announces Presentation Of Updated Cosibelimab Lung Cancer Results At The Society For Immunotherapy Of Cancer (SITC) 35th Anniversary Annual Meeting Benzinga

08:00AM EST -- 44.0% objective response rate and 10.3-monthmedian progression-free survival observed in non-small cell lung cancer (NSCLC) cohort -- Phase 3 registration-enablingtrial planned in first-line metastatic NSCLC GlobeNewswire Inc

Nov 4, 2020

05:14PM EST Checkpoint Therapeutics Q3 EPS $(0.09) Up From $(0.15) YoY Benzinga

04:25PM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights. GlobeNewswire Inc

Nov 2, 2020

07:08AM EST Checkpoint Therapeutics Expands its Manufacturing Partnership with Samsung Biologics for its Lead Product Candidate Benzinga

07:01AM EST Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership PR Newswire

Sep 29, 2020

09:06AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:47AM EDT HC Wainwright & Co. Maintains Buy on Checkpoint Therapeutics, Raises Price Target to $17 Benzinga

Sep 18, 2020

10:17AM EDT Mid-Morning Market Update: Markets Mixed; US Consumer Sentiment Rises In September Benzinga

Sep 17, 2020

05:27PM EDT Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering GlobeNewswire Inc

05:21PM EDT Checkpoint Therapeutics Suspended Selling Co's Common Stock Under Controlled Equity Offering Sales Agreement Dated Nov. 9, 2017 Benzinga

06:42AM EDT Checkpoint Therapeutics Report Updated Interim Results From Phase 1 Clinical Trial Of Cosibelimab RTTNews

06:33AM EDT Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma Benzinga

06:30AM EDT -- 51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort -- Interim results presented at ESMO Virtual Congress 2020 -- On track to report full top-line results in mid-2021 -- Potentially favorable safety profile compared to anti-PD-1 therapies -- Market-disruptive pricing planned in $25 billion PD-(L)1 market GlobeNewswire Inc

Sep 14, 2020

07:19AM EDT Checkpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress Benzinga

Aug 17, 2020

08:00AM EDT Checkpoint Therapeutics to Present at Virtual Corporate Access GlobeNewswire Inc

Aug 12, 2020

07:30AM EDT Fortress Biotech Announces Virtual Two-Day Corporate Access Summit GlobeNewswire Inc

Aug 5, 2020

05:30PM EDT Checkpoint Therapeutics Q2 EPS $(0.09) Up From $(0.15) YoY, Sales $42.00K Down From $1.05M YoY Benzinga

Jul 27, 2020

07:34AM EDT Checkpoint Therapeutics To Present Cosibelimab Interim Results From Registration-Enabling Trial At ESMO Virtual Congress 2020 Benzinga

07:30AM EDT -- Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma -- Over 50% of enrollment target achieved; full enrollment expected around year-end -- Potential for cosibelimab to be a best-in-class product with market disruptive pricing in a $25 billion PD-(L)1 class GlobeNewswire Inc

Jul 17, 2020

10:23AM EDT Shares of Checkpoint Therapeutics, Inc. (CKPT) are currently gaining nearly 45% on Friday morning despite no stock-specific news to drive the shares. Most of the US stocks are trading higher today as investors are optimistic going forward driven by the promising study results of COVID-19 vaccine. RTTNews

Share